<p>, /PRNewswire/ -- <strong>Sera Prognostics, Inc.</strong>，怀孕公司®（&#34;Sera&#34;或&#34;公司&#34;）（纳斯达克：SERA），专注于通过向医生和患者提供创新的妊娠生物标志物信息来改善母婴健康，今天宣布其承销的公开发行 1,250,000 股 A 类普通股的定价，公开发行价格为每股 4.00 美元，并且为了某些投资者提供 A 类普通股的替代，预先融资的认股权证可购买 11,250,000 股 A 类普通股，公开发行价格为每个预先融资的认股权证 3.9999 美元，这等于 A 类普通股每股的公开发行价格减去每个预先融资的认股权证的 0.0001 美元行使价格，以上均为承销折扣和佣金之前的金额。预计此次发行的总收益在扣除承销折扣和佣金及 Sera 应支付的其他发行费用之前约为 5000 万美元。Sera 已授予承销商 30 天的选择权，以公开发行价格购买最多 1,875,000 股 A 类普通股，扣除承销折扣和佣金。预先融资的认股权证将立即可行使，并且可以在其原始发行后随时行使。所有股份和预先融资的认股权证均由 Sera 提供。此次发行预计将在 2025 年 2 月 12 日完成，前提是满足惯例的交割条件。</p>
<p>Jefferies、TD Cowen 和 William Blair 担任联合账簿管理人，RBC Capital Markets 担任本次发行的账簿管理人。</p>
<p>Sera 打算将此次发行的净收益用于扩大其在美国的商业基础设施和能力，加快在欧盟扩展的准备工作，资助旨在增加 PreTRM 测试采用率的额外研究，包括可能向美国食品和药物管理局（&#34;FDA&#34;）提交申请，寻求对 PreTRM 测试的广泛批准，以及用于一般企业用途。</p>
<p>关于本次承销发行的证券的货架注册声明（表格 S-3，文件编号 333-281347）已于 2024 年 8 月 7 日向证券交易委员会（&#34;SEC&#34;）提交，并于 2024 年 8 月 13 日获得有效。此次发行仅通过补充招股说明书和伴随的招股说明书进行，这些文件构成注册声明的一部分。与此次发行相关的初步补充招股说明书和伴随的招股说明书已提交给 SEC，并可在 SEC 的网站 www.sec.gov 上获得。与此次发行相关的最终补充招股说明书将提交给 SEC。最终补充招股说明书和伴随的招股说明书的副本在可用时可从 Jefferies LLC 获取，注意：股权承销招股说明书部门，520 Madison Avenue, New York, NY 10022，电话 877-821-7388 或通过电子邮件联系 [email protected]；TD Securities (USA) LLC，1 Vanderbilt Avenue, New York, NY 10017，电话 855-495-9846，或通过电子邮件联系 [email protected]；或 William Blair &amp; Company, L.L.C.，William Blair 大厦，150 North Riverside Plaza, Chicago, Illinois 60606，电话 (800) 621-0687 或通过电子邮件联系 [email protected]。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他管辖区进行这些证券的销售，除非在该州或其他管辖区的证券法下注册或资格获得之前，此类要约、邀请或销售是非法的。</p>
<p><strong>关于 Sera Prognostics, Inc.</strong></p>
<p>Sera Prognostics 是一家领先的健康诊断公司，致力于通过精准的妊娠护理改善女性和婴儿的生活。Sera 的使命是提供早期、关键的妊娠信息，以改善母亲和新生儿的健康，从而降低医疗服务的成本。Sera 拥有一系列创新的诊断测试，专注于早期预测早产风险和其他妊娠并发症。Sera 的精准医学 PreTRM®测试向医生报告妊娠中自发性早产的个体化风险，使得对高风险女性进行更早的主动干预成为可能。Sera Prognostics 总部位于犹他州盐湖城。</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”，包括与我们满足与公开发行相关的惯常成交条件、预期公开发行的成交日期、我们在公开发行中出售证券、预期的总收益金额以及我们对公开发行收益的预期使用相关的声明。这些 “前瞻性声明” 基于管理层对未来事件的当前预期，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中所列或暗示的结果存在重大和不利的差异。这些风险和不确定性包括但不限于：与市场条件相关的不确定性以及公开发行是否能够按预期条款完成，或根本无法完成，净亏损、现金生成以及可能需要筹集更多资本；PreTRM 测试的收入占公司迄今为止几乎所有收入的比例；对 PreTRM 测试的广泛科学和市场接受的需求；集中数量的主要客户；我们推出新产品的能力；潜在竞争；我们的专有生物库；关键供应商；可寻址市场机会的总估计和市场增长的预测；潜在的第三方支付者覆盖和报销；适用于 PreTRM 测试的新报销方法，包括这些代码的新 CPT 代码和支付率；FDA 对实验室开发测试的监管变化；保护我们测试和市场地位的知识产权；以及在我们向证券交易委员会提交的《10-K 表格年报》和《10-Q 表格季报》中讨论的 “风险因素” 标题下的其他因素，以及不时在我们向证券交易委员会提交的定期和当前报告中更新的这些风险因素。本新闻稿中的所有信息均为发布之日的信息，公司不承担更新该信息的义务，除非法律要求。</p>
<p>来源：Sera Prognostics, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjEwJk5ld3NJdGVtSWQ9TEExNjM0MiZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTAyMjQxUFJfTkVXU19VU1BSX19fX19MQTE2MzQy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjEwJk5ld3NJdGVtSWQ9TEExNjM0MiZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTAyMjQxUFJfTkVXU19VU1BSX19fX19MQTE2MzQy"/></p>

SERA

<p>Sera Prognostics, Inc. 宣布以每股 4.00 美元的价格公开发行 1,250,000 股 A 类普通股，并同时发行 11,250,000 股预付认股权证，每股价格为 3.9999 美元。此次发行预计将筹集约 5000 万美元，所得款项将用于扩展商业基础设施、为欧盟扩展做准备以及资助 PreTRM 测试的研究。此次发行预计将于 2025 年 2 月 12 日完成，需满足惯常条件，由 Jefferies、TD Cowen 和 William Blair 担任联合账簿管理人</p>

<p>, /PRNewswire/ -- <strong>Sera Prognostics, Inc.</strong>, The Pregnancy Company® (&#34;Sera&#34; or the &#34;Company&#34;) (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common stock less the $0.0001 per share exercise price of each pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sera, are expected to be approximately $50 million. Sera has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issuance. All of the shares and pre-funded warrants are being offered by Sera. The offering is expected to close on February 12, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- <strong>Sera Prognostics, Inc.</strong>，怀孕公司®（&#34;Sera&#34;或&#34;公司&#34;）（纳斯达克：SERA），专注于通过向医生和患者提供创新的妊娠生物标志物信息来改善母婴健康，今天宣布其承销的公开发行 1,250,000 股 A 类普通股的定价，公开发行价格为每股 4.00 美元，并且为了某些投资者提供 A 类普通股的替代，预先融资的认股权证可购买 11,250,000 股 A 类普通股，公开发行价格为每个预先融资的认股权证 3.9999 美元，这等于 A 类普通股每股的公开发行价格减去每个预先融资的认股权证的 0.0001 美元行使价格，以上均为承销折扣和佣金之前的金额。预计此次发行的总收益在扣除承销折扣和佣金及 Sera 应支付的其他发行费用之前约为 5000 万美元。Sera 已授予承销商 30 天的选择权，以公开发行价格购买最多 1,875,000 股 A 类普通股，扣除承销折扣和佣金。预先融资的认股权证将立即可行使，并且可以在其原始发行后随时行使。所有股份和预先融资的认股权证均由 Sera 提供。此次发行预计将在 2025 年 2 月 12 日完成，前提是满足惯例的交割条件。</p>
</div><p>Jefferies, TD Cowen and William Blair are acting as joint book-running managers and RBC Capital Markets is acting as a bookrunner for the offering.</p>
<div class="lb-trans"><p>Jefferies、TD Cowen 和 William Blair 担任联合账簿管理人，RBC Capital Markets 担任本次发行的账簿管理人。</p>
</div><p>Sera intends to use the net proceeds from the offering to expand its commercial infrastructure and capabilities in the United States, accelerate preparations for expansion in the European Union, fund additional studies designed to increase adoption of the PreTRM test, including a potential submission to the U.S. Food and Drug Administration (the &#34;FDA&#34;) seeking broad approval of the PreTRM test, and for general corporate purposes.</p>
<div class="lb-trans"><p>Sera 打算将此次发行的净收益用于扩大其在美国的商业基础设施和能力，加快在欧盟扩展的准备工作，资助旨在增加 PreTRM 测试采用率的额外研究，包括可能向美国食品和药物管理局（&#34;FDA&#34;）提交申请，寻求对 PreTRM 测试的广泛批准，以及用于一般企业用途。</p>
</div><p>A shelf registration statement on Form S-3 (File No. 333-281347) relating to the securities offered in the underwritten offering was filed with the Securities and Exchange Commission (the &#34;SEC&#34;) on August 7, 2024 and declared effective on August 13, 2024. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website located at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at [email protected]; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at 855-495-9846, or by email at [email protected]; or William Blair &amp; Company, L.L.C., The William Blair Building, 150 North Riverside Plaza, Chicago, Illinois 60606, or by telephone at (800) 621-0687 or email at [email protected].</p>
<div class="lb-trans"><p>关于本次承销发行的证券的货架注册声明（表格 S-3，文件编号 333-281347）已于 2024 年 8 月 7 日向证券交易委员会（&#34;SEC&#34;）提交，并于 2024 年 8 月 13 日获得有效。此次发行仅通过补充招股说明书和伴随的招股说明书进行，这些文件构成注册声明的一部分。与此次发行相关的初步补充招股说明书和伴随的招股说明书已提交给 SEC，并可在 SEC 的网站 www.sec.gov 上获得。与此次发行相关的最终补充招股说明书将提交给 SEC。最终补充招股说明书和伴随的招股说明书的副本在可用时可从 Jefferies LLC 获取，注意：股权承销招股说明书部门，520 Madison Avenue, New York, NY 10022，电话 877-821-7388 或通过电子邮件联系 [email protected]；TD Securities (USA) LLC，1 Vanderbilt Avenue, New York, NY 10017，电话 855-495-9846，或通过电子邮件联系 [email protected]；或 William Blair &amp; Company, L.L.C.，William Blair 大厦，150 North Riverside Plaza, Chicago, Illinois 60606，电话 (800) 621-0687 或通过电子邮件联系 [email protected]。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何州或其他管辖区进行这些证券的销售，除非在该州或其他管辖区的证券法下注册或资格获得之前，此类要约、邀请或销售是非法的。</p>
</div><p><strong>About Sera Prognostics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Sera Prognostics, Inc.</strong></p>
</div><p>Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.</p>
<div class="lb-trans"><p>Sera Prognostics 是一家领先的健康诊断公司，致力于通过精准的妊娠护理改善女性和婴儿的生活。Sera 的使命是提供早期、关键的妊娠信息，以改善母亲和新生儿的健康，从而降低医疗服务的成本。Sera 拥有一系列创新的诊断测试，专注于早期预测早产风险和其他妊娠并发症。Sera 的精准医学 PreTRM®测试向医生报告妊娠中自发性早产的个体化风险，使得对高风险女性进行更早的主动干预成为可能。Sera Prognostics 总部位于犹他州盐湖城。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our satisfaction of customary closing conditions related to the public offering, the anticipated closing date of the public offering, the sale of our securities in the public offering, the expected amount of the gross proceeds and our anticipated use of proceeds of the public offering. These &#34;forward-looking statements&#34; are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or at all, net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading &#34;Risk Factors&#34; contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的 “前瞻性声明”，包括与我们满足与公开发行相关的惯常成交条件、预期公开发行的成交日期、我们在公开发行中出售证券、预期的总收益金额以及我们对公开发行收益的预期使用相关的声明。这些 “前瞻性声明” 基于管理层对未来事件的当前预期，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中所列或暗示的结果存在重大和不利的差异。这些风险和不确定性包括但不限于：与市场条件相关的不确定性以及公开发行是否能够按预期条款完成，或根本无法完成，净亏损、现金生成以及可能需要筹集更多资本；PreTRM 测试的收入占公司迄今为止几乎所有收入的比例；对 PreTRM 测试的广泛科学和市场接受的需求；集中数量的主要客户；我们推出新产品的能力；潜在竞争；我们的专有生物库；关键供应商；可寻址市场机会的总估计和市场增长的预测；潜在的第三方支付者覆盖和报销；适用于 PreTRM 测试的新报销方法，包括这些代码的新 CPT 代码和支付率；FDA 对实验室开发测试的监管变化；保护我们测试和市场地位的知识产权；以及在我们向证券交易委员会提交的《10-K 表格年报》和《10-Q 表格季报》中讨论的 “风险因素” 标题下的其他因素，以及不时在我们向证券交易委员会提交的定期和当前报告中更新的这些风险因素。本新闻稿中的所有信息均为发布之日的信息，公司不承担更新该信息的义务，除非法律要求。</p>
</div><p>SOURCE Sera Prognostics, Inc.</p>
<div class="lb-trans"><p>来源：Sera Prognostics, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjEwJk5ld3NJdGVtSWQ9TEExNjM0MiZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTAyMjQxUFJfTkVXU19VU1BSX19fX19MQTE2MzQy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA16342&amp;Transmission_Id=202502102241PR_NEWS_USPR_____LA16342&amp;DateId=20250210"/></p>

Sera Prognostics 宣布 5000 万美元公开发行的定价